Skip to main content

Table 5 Characteristics of the CNS lupus patients with large abnormal MRI signals

From: Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study

Case

Duration of SLE (yrs)

SLEDAI

SLEDAI without CNS

aPL*

SLE-related CNS syndrome

Treatment

Clinical outcome of CNS lupus

MRI change

1

0

31

15

Positive

Seizure disorder, Headache

Steroids

Improve

Improve

2

0

11

3

Negative

Acute confusional state

Steroids + CPA

Improve

Improve

3

1

24

8

Negative

Demyelinating syndrome, Acute confusional state

Steroids + CPA

Improve

Improve

4

9

29

5

Positive

Demyelinating syndrome, Seizure disorder, Acute confusional state

Steroids + CPA

Improve

Improve

5

4

16

0

Negative

Demyelinating syndrome, Acute confusional state

Steroids + CPA

No change

No change

6

8

10

2

Negative

Cerebrovascular disease

Steroids + CPA + anticoagulant

No change

No change

7

5

22

6

Negative

Acute confusional state

Steroids + CPA

No change

Deteriorate

  1. CNS: central nervous system; MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index; aPL: antiphospholipid antibody; CPA: cyclophosphamide.
  2. *aPL includes lupus anticoagulant, anti-cardiolipin antibodies, and anti-β2GPI antibodies.
  3. †The case numbers given are not identifying numbers.